Effects of zoledronic acid on metastatic bone pain in cancer of the prostate: A randomised controlled trial
##plugins.themes.bootstrap3.article.main##
Resumo
Background: Advanced cancer of the prostate often
causes pain that can be severe requiring palliation
with analgesics. Zoledronic acid, a third-generation
bisphosphonate, has not been primarily used as an
adjunct to treat pain in patients with metastatic bone
secondary to advanced prostate cancer in Nigeria.
The study investigated the effects of 3 doses of
Zoledronic acid, at 4-weekly intervals, in addition to
the analgesic regimen of oral morphine, diclofenac,
paracetamol and amitriptyline, on bone pain in patients
with metastatic prostate cancer .
Methods: A prospective randomized open-labelled
trial in which forty patients with moderate to severe
bone pain due to metastatic prostate cancer were
recruited after institutional ethics approval. Patients
were assigned to two groups: The Control (C) group
received liquid oral morphine, diclofenac, paracetamol
and amitriptyline. Zoledronic acid (ZG) group received
3 doses of Zoledronic acid at 4-weekly intervals in
addition to liquid morphine, diclofenac, paracetamol and
amitriptyline. Severity of pain and quality of life (QoL)
were measured at baseline and weekly for 12 weeks.
Data were analysed using means, range, standard
deviations and proportions while independent t-test was
used to compare the variables between the two groups.
Results: Demographic variables, baseline pain scores
and quality of life between the 2 groups were similar.
There was a statistically significant improvement in
pain score in the Zoledronic acid group (1.38±0.53
vs 2.13±0.94) post-intervention, (p = 0.004).
Conclusion: The administration of three doses of
Zoledronic acid at 4-weekly intervals significantly
improved bone pain score during the 12-weeks follow
up in patients with advanced prostate cancer.
##plugins.themes.bootstrap3.article.details##
Secção
Referências
Ali E, Serbulent GB, Hassan S and Mustafa EG.
Pain management in prostate cancer. Open J of
Urol 2012; 2: 164-172.
Bienz M and Saad F. Management of bone
metastases in prostate cancer: a review. Curr
Opin Support Palliat Care. 2015; 9(3):261-7.
Ogunbiyi JO and Shittu OB. Increased incidence
of prostatic cancer in Nigerians. J Natl Med
Assoc. 1999; 91(3):159-164.
Badmus TA, Adesunkanmi AR, Yussuf BM et
al. Burden of Prostate cancer in southwestern
Nigeria. Urology 2010; 76 (2): 412-6.
Saad F, Gleason DM, Murray R, et al. A
Randomized, Placebo-controlled Trial of
Zoledronic Acid in Patients with Hormonerefractory Metastatic Prostate Carcinoma.
Journal of the National Cancer Institute 2002;
(19):1458-1468.
Ripamonti C and Fulfaro F. Malignant bone pain:
Pathophysiology and Treatments. Current
Review of Pain 2000; 4 (3):187-196.
Donnelly S, Davis M P, Walsh D and Naughton
M. Morphine in cancer pain management: a
practical guide. Support Care Cancer 2002;
(1):13-35.
Wiffen P J, Wee B and Moore R A. Oral
morphine for cancer pain. Cochrane Database
Syst Rev 2013 ;( 7):CD003868.
Eyelade OR, Ajayi IO, Elumelu TN, Soyannwo
OA and Akinyemi OA. Oral Morphine
effectiveness in Nigerian patients with advanced
cancer. J. Pain Palliat Care Pharmacother. 2012;
(1):24-9.
Maltzman JD and Millar LB. Bone metastasis
treatment with Bisphosphonates. Cancer
Resources for Patients and Healthcare
Professionals. Available at http://
www.oncolink.org.org/. Accessed on 13/06/2017.
Wong R and Wiffen PJ. Bisphosphonates for the
relief of pain secondary to bone metastasis
(Cochrane Review). In: The Cochrane Library,
:4.
Polascik TJ and Mouraviev V. Zoledronic Acid
in the management of metastatic bone disease.
Ther. Clin Risk Manag 2008; 4(1): 261-268.
Weinfurt KP, Anstrom KJ, Castel LD, Schulman
KA and Saad F. Effect of zoledronic acid on pain
associated with bone metastasis in patients with
prostate cancer. Annals of Oncology 2006;17(6):
-989.
Kourie HR, Sntoun J, El Rassy E, et al.
Osteonecrosis of the jaw during bi-yearly
treatment with zoledronic acid for aromatase
inhibitor associated bone loss in early breast
cancer: A literature review. J Bone Oncol.
;4(3):77-79.
Dore F, Filippi L, Biasotto M, et al. Bone
Scintigraphy and SPECT/CT of bisphosphonateinduced osteonecrosis of the jaw. J Nucl Med.
; 50(1):30-5.
Howard (Jack) W, Jill OJ. Performance Status
in Patients with Cancer . JAMA Oncol.
;1(7):998.
Oken MM, Creech RH, Tormey DC, et al.
“Toxicity and response criteria of the Eastern
Cooperative Oncology Group”. Am. J. Clin.
Oncol.1982;5 (6): 649–655.
Himelstein AL, Foster JC, Khatcheressian JL,et
al. Effects of Longer-Interval vs Standard Dosing
of Zoledronic Acid on Skeletal Events in Patients
with Bone Metastases: A Randomized Clinical
Trial. JAMA. 2017; 317 (1):48-58
Gravalos C, Rodrýguez C, Sabin A, et al. SEOM
Clinical Guideline for bone metastases from solid
tumours. Clin Transl Oncol. 2016; 18:1243–1253.
Paez Borda A, Charnay-Sonnek F, Fonteyne V
and Papaioannou EG. Pain Management in
Urological Cancers. The European Association
of Urology (EAU) Guidelines on Pain
Management and Palliative: Pain Management
and Palliative care - UPDATE MARCH 2013:7-
Accessed on 23/02/18
Olapade-Olaopa EO, Owoaje ET, Kola L, et al.
Knowledge and perception of Nigerian Men 40
years and above regarding prostate cancer. J
West Afr Coll Surg. 2014; 4(1):1-16.
Nakamura N, Yamadai Y, Rosser CJ, et al. The
use of zoledronic acid in Japanese men with stage
D2 prostate cancer. Oncology letters 2010; 1:
-16.
Saad F, Gleason DM, Murray R, et al. Longterm efficacy of zoledronic acid for the
prevention of skeletal complications in patients
with metastatic hormone-refractory prostate
cancer. J. Natl Cancer Inst 2004; 96: 879-82.
Effects of zoledronic acid on metastatic bone pain in cancer of the prostate 273
Kmetec A and Hajdinjak T. Evaluation of safety
and analgesic consumption in patients with
advanced cancer treated with zoledronic acid.
Radiol Oncol 2013; 47(3): 289-295.
El-Amim J and Aragon-Ching JB. Targeting
Bone Metastases in Metastatic CastrationResistant Prostate Cancer. Clinical Medicine
Insights: Oncology 2016:10(s1): 10-19.
Osman H, Shreshtha S, Temin S, et al. Palliative
Care in the Global Setting: ASCO ResourceStratified Practice Guideline. Journal of Global
Oncology 2018; 4:1-24.
Adenipekun A, Onibokun A, Elumelu TN and
Soyannwo OA. Knowledge and attitudes of
terminally ill patients and their family to palliative
care and hospice services in Nigeria. Niger J
Clin Pract. 2005; 8(1):19-22.
Saad F: Clinical benefit of zoledronic acid for
the prevention of skeletal complications in
advanced prostate cancer. Clin. Prostate cancer
; 4: 31-37.
So A, Chin J, Fleshner N Saad F. Management
of skeletal-related events in patients with
advanced prostate cancer and bone metastases:
incorporating new agents into clinical practice.
Can Urol Assoc J. 2012 6(6):465-470.
Lazarovici TS, Yahalom R, Taicher S, Elad S,
Hardan I, Yarom N. Biphosphonate-related
osteonecrosis of the jaws: a single center study
of 101 patients. Journal of Oral and Maxillofacial
Surgery. 2009; 67(4): 850-855.
Joshi JK, Kushner GM, Bhatt G, Bhatt AD,
Civelek AC. Role of nuclear medicine imaging
in recognizing different causes of osteonecrosis
of the jaw. Clinical Nuclear Medicine. 2013;
(1): 40-43.
Bamias A, Kastritis E, Bamia C, et al.
Osteonecrosis of the jaw in cancer after
treatment with bisphosphonates: incidence and
risk factors. J Clin Oncol. 2005; 23(34):8580-7.
Woo-Sung C, Jae-Il L, Hyun-Joong Y, Chang-Ki
M and Sang-Hwa L. Medication-related
osteonecrosis of the jaw: a preliminary
retrospective study of 130 patients with multiple
myeloma. Maxillofacial Plastic and
Reconstructive Surgery 2017; 39:1-10.